Such treatments were considered in 15 of the 23 NSCLC dossiers for the following mutations: anaplastic lymphoma kinase (ALK), rapidly accelerated fibrosarcoma-isoform B (BRAF), epidermal growth factor receptor (EGFR) and the C-ros oncogene 1 (ROS1). Here, ROS1 is linked to fibrosarcoma.